Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: Itraconazole

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 83, Issue 3, 2013, Pages 378-387

  Taupitz, Thomas ^a   Dressman, Jennifer B ^a   Buchanan, Charles M ^b   Klein, Sandra ^b  

^a EASTMAN CHEMICAL COMPANY   (United States)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Intestinal drug precipitation; IVIVC; PBPK modelling; Solubility enhancement; Ternary cyclodextrin complexes; Transfer experiments

Indexed keywords

BETA CYCLODEXTRIN; ITRACONAZOLE; POLYMER; WATER;

AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE FLUID; MAXIMUM PLASMA CONCENTRATION; PRECIPITATION; STOMACH EMPTYING; X RAY DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CYCLODEXTRINS; ITRACONAZOLE; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; POLYMERS; POWDER DIFFRACTION; SOLUBILITY; WATER;

EID: 84875214001     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.11.003     Document Type: Article

References (38)

1. P. Gribbon, and A. Sewing High-throughput drug discovery: what can we expect from HTS? Drug Discov. Today 10 2005 17 22
2. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
3. F. Nimmerfall, and J. Rosenthaler Dependence of area under the curve on proquazone particle-size and in vitro dissolution rate J. Pharm. Sci. 69 1980 605 607
4. K. Sigfridsson, A.J. Lundqvist, and M. Strimfors Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development Drug Dev. Ind. Pharm. 35 2009 1479 1486
5. B.C. Hancock, and G. Zograf Characteristics and significance of the amorphous state in pharmaceutical systems J. Pharm. Sci. 86 1997 1 12
6. T. Loftsson, and M.E. Brewster Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization J. Pharm. Sci. 85 1996 1017 1025
7. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60
8. T. Ohara, S. Kitamura, T. Kitagawa, and K. Terada Dissolution mechanism of poorly water-soluble drug from extended release solid dispersion system with ethylcellulose and hydroxypropylmethylcellulose Int. J. Pharm. 302 2005 95 102
9. A.H. Goldberg, M. Gibaldi, and J.L. Kanig Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. 2. Experimental evaluation of a eutectic mixture-urea-acetaminophen system J. Pharm. Sci. 55 1966 482 484
10. N. Tanaka, K. Imai, K. Okimoto, S. Ueda, Y. Tokunaga, R. Ibuki, K. Higaki, and T. Kimura Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation J. Control. Rel. 112 2006 51 56
11. E. Karavas, G. Ktistis, A. Xenakis, and E. Georgarakis Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone Eur. J. Pharm. Biopharm. 63 2006 103 114
12. G.R. Lloyd, D.Q.M. Craig, and A. Smith A calorimetric investigation into the interaction between paracetamol and polyethlene glycol 4000 in physical mixes and solid dispersions Eur. J. Pharm. Biopharm. 48 1999 59 65
13. A. Paradkar, V.B. Pokharkar, L.P. Mandpe, M.N. Padamwar, A.A. Ambike, and K.R. Mahadik Development, characterization and stabilization of amorphous form of a low T-g drug Powder Technol. 167 2006 20 25
14. BASF, Technical Information Soluplus, 2009, pp. 1-8.
15. M.E. Davis, and M.E. Brewster Cyclodextrin-based pharmaceutics: past, present and future Nat. Rev. Drug Discov. 3 2004 1023 1035
16. T. Loftsson, M. Masson, and M.E. Brewster Self-association of cyclodextrins and cyclodextrin complexes J. Pharm. Sci. 93 2004 1091 1099
17. R.A. Rajewski, and V.J. Stella Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery J. Pharm. Sci. 85 1996 1142 1169
18. W. Saenger Cyclodextrin inclusion complexes Abstr. Papers Am. Chem. Soc. 179 1980 86
19. T. Loftsson, and M. Masson The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs J. Drug Del. Sci. Technol. 14 2004 35 43
20. T. Loftsson, M. Messner, S.V. Kurkov, M.E. Brewster, and P. Jansook Self-assembly of cyclodextrin complexes: aggregation of hydrocortisone/ cyclodextrin complexes Int. J. Pharm. 407 2011 174 183
21. R.A. Rajewski, G. Traiger, J. Bresnahan, P. Jaberaboansari, V.J. Stella, and D.O. Thompson preliminary safety evaluation of parenterally administered sulfoalkyl ether beta-cyclodextrin derivatives J. Pharm. Sci. 84 1995 927 932
22. D. Rong, and V.T. Dsouza A convenient method for functionalization of the 2-position of cyclodextrins Tetrahedron Lett. 31 1990 4275 4278
23. D. Juenemann, E. Jantratid, C. Wagner, C. Reppas, M. Vertzoni, and J.B. Dressman Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles Eur. J. Pharm. Biopharm. 77 2011 257 264
24. Y. Shono, E. Jantratid, and J.B. Dressman Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir Eur. J. Pharm. Biopharm. 79 2011 349 356
25. P. De Doncker, J. Decroix, G.E. Pierard, D. Roelant, R. Woestenborghs, P. Jacqmin, F. Odds, A. Heremans, P. Dockx, and D. Roseeuw Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole Arch Dermatol. 132 1996 34 41
26. J.D. Cleary, J.W. Taylor, and S.W. Chapman Itraconazole in antifungal therapy Ann. Pharmacother. 26 1992 502 509
27. C.M. Buchanan, N.L. Buchanan, K.J. Edgar, S. Klein, J.L. Little, M.G. Ramsey, K.M. Ruble, V.J. Wacher, and M.F. Wempe Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations J. Pharm. Sci. 96 2007 3100 3116
28. P. Augustijns, M. Van Speybroeck, R. Mols, R. Mellaerts, T. Do Thi, J.A. Martens, J. Van Humbeeck, P. Annaert, and G. Van den Mooter Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole Eur. J. Pharm. Biopharm. 75 2010 354 365
29. S. Klein The mini paddle apparatus-a useful tool in the early developmental stage? Experiences with immediate-release dosage forms Dissol. Technol. 13 2006 6 11
30. S. Klein, and V. Shah A standardized mini paddle apparatus as an alternative to the standard paddle AAPS PharmSciTech 9 2008 1179 1184
31. 3-transporters in the rat pancreatic duct J. Gen. Physiol. 104 1994 57 85
32. E.S. Kostewicz, M. Wunderlich, U. Brauns, R. Becker, T. Bock, and J.B. Dressman Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine J. Pharm. Pharmacol. 56 2004 43 51
33. E. Nicolaides, M. Symillides, J.B. Dressman, and C. Reppas Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration Pharm. Res. 18 2001 380 388
34. M. Vertzoni, J. Dressman, J. Butler, J. Hempenstall, and C. Reppas Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds Eur. J. Pharm. Biopharm. 60 2005 413 417
35. R. Takano, K. Furumoto, K. Shiraki, N. Takata, Y. Hayashi, Y. Aso, and S. Yamashita Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation Pharm. Res. 25 2008 2334 2344
36. S. Willmann, W. Schmitt, J. Keldenich, J. Lippert, and J.B. Dressman A physiological model for the estimation of the fraction dose absorbed in humans J. Med. Chem. 47 2004 4022 4031
37. C. Leuner, Verbesserung des Freisetzungsverhaltens von Itraconazol durch feste Dispersionen, Doctoral thesis, Frankfurt, Germany, 2004.
38. P. Augustijns, J. Brouwers, and M.E. Brewster Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. 98 2009 2549 2572